Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oncology > Eugene Heme Oncology > Flashcards

Eugene Heme Oncology Flashcards

1
Q

Cell Cycle Cancer examples

A

Hereditary Melanoma, Retinoblastoma, Li-Fraumeni Syndrome Catergory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

point mutation in cyclin-dependent kinase (cdk4) inhibitor on Chr9; insensitive to p16 inhibition

A

Hereditary Melanoma: Pathophysiology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Loss of RB (cell cycle control protein)

A

Retinoblastoma: Pathophysiology/Diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

tumor suppresor: when NOT phosphorylated, binds E2F to block transcription and cell division (inactive in most human cancers)

A

Rb pathway: Rb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

onco, TFs required for cell cycle progression, blocked by Rb binding

A

Rb pathway: E2F

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

onco, phosphorylate (inactivate) Rb

A

Rb pathway: Cdk4/Cyclin D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

tumor suppressor, downregulate Cdk4/Cyclin D activity

A

Rb pathway: p16

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Lots of cancers (breast, colon, etc.)

A

Li-Fraumeni Syndrome: Signs/Symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Inherited p53 mutation

A

Li-Fraumeni Syndrome: Pathophysiology/Diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

tumor suppressor, activates p53

A

p53 pathway: ATM (Li-Fraumeni)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

oncoprotein, inhibits p53

A

p53 pathway: Mdm2 (Li-Fraumeni)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

tumor suppressor, G1 cycle arrest allows for DNA repair in fibroblasts, some epithelial cells, apoptosis in thymocytes

A

p53 pathway: p53 (Li-Fraumeni)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

tumor suppressor, downstream of p53

A

p53 pathway: p21 (Li-Fraumeni)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

trisomy 21, Fanconi’s anemia, Li-Fraumeni

A

Acute Myloid Leukemia (AML): Inherited

Downs also ALL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Age (>60 yo = poor outcomes), rad exposure, MDS, myeloproliferative neoplasms (CML, PV, ET), prior chemo (alkylating agents for lymphoma, breast cancer; topoisomerase inhibitors for testicular cancer via 11q23 MLL gene deletion)

A

Acute Myeloid Leukemia (AML): Epi/Risk Factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

large, very granular cells with bilobed nuclei

A

Acute Myloid Leukemia: APL subtype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

blasts w/lots of cytoplasm, prominent nucleoli, granules and some maturing cells

A

Acute Myloid Leukemia: M2 subtype Histology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Sx: Anemia, infections, bleeding. Hemorrhage, skin or gum infiltration, no mediastinal masses, LAD and hepatosplenomegaly less likely

A

Acute Myeloid Leukemia (AML): Signs/Symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Generally poor (<60% @ 5yr); t(8;21)(15;17), inv(16) good, 5q, chemo or complex karyotype bad

A

Acute Myeloid Leukemia (AML): Prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

If good prognosis: 7+3: cytarabine x7d, doxorubicin x3d

A

Acute Myeloid Leukemia (AML): Treatment/Notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

AML by day 14 of cyta/doxo 7+3

A

hopefully shows aplastic marrow

if not salvage/clinical trial/palliation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Sx: Anemia, infections, high risk for hemorrhage; differentiation syndrome: fever, dyspnea, weight gain, pulmonary infiltrates, pleural and pericardial infusions

A

Acute Promyelocytic Leukemia (APL)(AML M3 Subtype)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Myeloblast/lymphoblast progenitor cell overgrowth; t(15;17) PML/RAR-alpha fusion transcript

A

Acute Promyelocytic Leukemia (APL)(AML M3 Subtype): Pathophysiology/Diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Acute Promyelocytic Leukemia (APL)(AML M3 Subtype): Prognosis

A

80-90% at five years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Sensitive to ATRA, may cause differentiation syndrome. Tx: dexamethasone, arsenic trioxide (ATO)

A

Acute Promyelocytic Leukemia (APL)(AML M3 Subtype): Treatment/Notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

myeloblast/lymphoblast progenitor cell overgrowth

A

Acute Leukemias (AML, APL, ALL): pathophysiology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

iliac crest bone biopsy, blood tests

A

Acute Leukemias (AML, APL, ALL): diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

leukostasis (AML>ALL, tx: leukaphoresis, hydroxyurea), DIC, tumor lysis syndrome

A

Acute Leukemias (AML, APL, ALL): complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Rare. Extremes of age, radiation, downs

A

Acute Lymphoblastic Leukemia (ALL): Epi/Risk Factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Sx: Anemia, infections, bleeding, ant. mediastinal mass, DIC, bone pain; rarely lymphadenopathy and hepatosplenomegaly

A

Acute Lymphoblastic Leukemia (ALL): Signs/Symptoms/Findings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Mediastinal mass, especially

A

T-ALL common presentation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

way high lymphocytes, large cells, high N:C ratio, prominent nucleoli, no granules, open chromatin, lack of PMNs and platelets

A

Acute Lymphoblastic Leukemia histology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

TdT+, Ig+, CD10+

A

B-cell ALL surface markers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

TdT+, CD2+, CD3+

A

T-cell ALL surface markers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

peds: 10; adults >60

A

ALL adverse prognostic factors: age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

> 30k (B), or >100k (T)

A

ALL adverse prognostic factors: WBC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

philedelphia: t(9;22), found in adults >60; t(4;11), found in peds <1

A

ALL adverse prognostic factors: cytogenetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Acute Lymphoblastic Leukemia (ALL): Prognosis

A

> 90% five year survival. Philadelphia chromosome bad

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Induction w/ CHOP; CNS prophylaxis, stem cell xplant, maintenance (prednisone, mercaptopurine, MTX)

A

Acute Lymphoblastic Leukemia (ALL): Treatment/Notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

myelodysplasia 5 ways

A

Mylodystplastic syndrome, 5q, Polycythemia Vera, Essential thrombocythemia, primary myelofibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Risk of transformation to AML

A

Myelodysplastic Syndrome (MDS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

High blasts, proliferation, apoptosis; low WBC, RBC, plts. anemia

A

Myelodysplastic Syndrome (MDS): Signs/Symptoms/Findings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Stem cell disorder: bad hematopoesis leads to defects in all non lymphoid lined, cytopenia due to TNF-mediated apoptosis. De novo or exposure: chemo, radiation, benzenes

A

Myelodysplastic Syndrome MDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Low risk: Lenalidomide if 5q del, growth factor therapy if not
High risk or EPOdecitabine if no Sx
stem cell transplant curative

A

Myelodysplastic Syndrome (MDS): Treatment/Notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Deletion leads to Anemia with increased PLT (megakaryocytes slow-growing)

A

5q Syndrome, MDS subtype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Del(5q31) leads to del(RPS14) leads to death of rapidly dividing cells (erythroid). Low AML conversion

A

5q Syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

MPN: expansion of RBC lineage

A

Polycythemia Vera: Findings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

itching, ruddy complexion, splenomegaly, early saiety, DVT or PE

A

Polycythemia Vera: Symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

JAK2V617F in 92% of cases leads to increase in all cell types (mainly RBC lineage)

A

Polycythemia Vera: Pathophysiology/Diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

MPN w/Good prognosis. 3% yearly mortality

A

Polycythemia Vera: Prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Platelet lineage expansion. increased PLT, normal Hgb

A

Essential Thrombocytosis (Primary Thrombocythemia): Findings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

megokaryocytes in bone marrow, exclusion, JAK2 mut in 42%

A

Essential Thrombocytosis (Primary Thrombocythemia): Pathophysiology/Diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

low risk: low dose aspirin; high risk (>60, past thrombosis, CV risk): low dose aspirin, hydroxyurea

A

Essential Thrombocytosis (Primary Thrombocythemia): Treatment/Notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

teardrop RBCs (dacrocytes), increased LDH

A

Primary Myelofibrosis (Idiopathic Myelofibrosis): Findings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

bleeding, anemia, infxn, cachexia, fullness, splenomagaly

A

Primary Myelofibrosis (Idiopathic Myelofibrosis): Signs/Symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Marrow fibrosis, extra-medullary hematopoiesis

A

Primary Myelofibrosis (Idiopathic Myelofibrosis): Pathophysiology/Diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

5 year survival, CALR better than JAK2

A

Primary Myelofibrosis: Prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

epo/transfusion, hydroxyurea, thalidomide/steroids, SC transplant (cure!), JAK inhibitors

A

Primary Myelofibrosis (Idiopathic Myelofibrosis): Treatment/Notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

increased mature and immature myeloid cells, basophilia, decreased hgb/hct, increased platelets (thrombocytosis)

A

Chronic Myelogenous Leukemia (CML): Findings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

fatigue, fullness, hepatosplenomagaly, weight loss, ecchymoses, anemia

A

Chronic Myelogenous Leukemia (CML): Signs/Symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

abl is oncogene, MR3 (major) = >3log bcr-abl reduction, MR4.5 (complete) = 4.5 log reduction

A

chronic myelogenous leukemia (CML): genetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

t(9;22) leads to Bcr/Abl fusion gene on Philadelphia chromosome (22q-) leads to increased tyrosine kinase activity

A

Chronic Myelogenous Leukemia (CML): Pathophysiology/Diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

slow-growing Ca harder to kill. Chronic phase of high blood counts (4-6 years) leads to accelerated phase (`1y) leads to blast crisis, AML (3-6 mos to death)

A

Chronic Myelogenous Leukemia (CML): Prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Tx: Imatinib (Gleevec) ± xplant
Progresses from chronic (splenomegaly or asymptomatic) leads to accelerated (anemia, decreased PLT) leads to blast crisis (~AML)

A

Chronic Myelogenous Leukemia (CML): Treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

most common leukemia, >60 yo, not radiation!

A

Chronic Lymphocytic Leukemia (CLL): Epi/Risk Factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Sx: Asymptomatic increased WBC, lymphadenopathy, splenomegaly, sino-pulmonary infxns, gradual onset fatigue, dyspnea, dizziness, weight loss

A

Chronic Lymphocytic Leukemia (CLL): Signs/Symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

lymphocytosis (small w/clumped chromatin), smudge cells

A

Chronic Lymphocytic Leukemia (CLL): findings

68
Q

CD20+***, CD5+

A

Chronic Lymphocytic Leukemia (CLL): Diagnosis (flow cytometry)

69
Q

Dx: CBC, peripheral blood smear/FACS, no marrow biopsy

A

Chronic Lymphocytic Leukemia (CLL): Pathophysiology/Diagnosis

70
Q

Largely incurable except in rare cases with bone marrow xplant (slow-growing Ca harder to kill); Prognosis: 13q- good, 11q- & 17p- bad

A

Chronic Lymphocytic Leukemia (CLL): Prognosis

71
Q

Tx: FCR (fludarabine, cyclo-phosphamide, rituximab), alemtuzumab, idelalisib, ibrutinib, allogenic xplant (only cure, but 20% fatal)

A

Chronic Lymphocytic Leukemia (CLL): Treatment

72
Q

AIHA, ITP, pure red cell aplasia ( decreased RBCs, severe anemia), decreased Ig’s (chronic infxn)

A

Chronic Lymphocytic Leukemia (CLL): Complications

73
Q

Aberrant lymphocytes in blood or marrow, <5000 lymphocytes, not considered malignancy but can be risk for one

A

Monoclonal B-Lymphocytosis

74
Q

Most common lymphoma, 25K/yr

A

Diffuse Large B-Cell Lymphoma (DLBCL): Epi/Risk Factors

75
Q

Large lymphocytes (4-5x normal), diffuse growth

A

Diffuse Large B-Cell Lymphoma (DLBCL): Findings

76
Q

germinal center markers (CD19, 20, 10; BC16)

A

Diffuse Large B-Cell Lymphoma (DLBCL): IHC markers

77
Q

lymphadenopathy, night sweats, fatigue

A

Diffuse Large B-Cell Lymphoma (DLBCL): Signs/Symptoms

78
Q

BCL6 overexpression (GC type), NFkB addition (non-GC), or Type 3 (primary mediastinal) subtypes

A

Diffuse Large B-Cell Lymphoma (DLBCL): Pathophysiology/Diagnosis

79
Q

Not great (50% 10 yr in germinal-center-like, less good in ABC, PMBL)

A

Diffuse Large B-Cell Lymphoma (DLBCL): Prognosis

80
Q

Tx: R-CHOP (Rituximab, Cyclophosphamide, Hdoxorubin, Ovincristine, Prednisone
immunodeficiency-associated, primary effusion lymphoma

A

Diffuse Large B-Cell Lymphoma (DLBCL): Treatment/Notes

81
Q

All respond better to infusional chemo and etoposide

A

Special situational and subtype DLBCL

82
Q

burkitts or DLBCL of germinal center origin + HIV

A

HIV DLBCL (well controlled)

83
Q

primary effusion lymphoma, post-germainal center immunoblastic lymphoma, plasmoblastic lymphoma, bad prognosis

A

HIV DLBCL (not controlled)

84
Q

hodgkin’s-like, lymphoid or plasmacytic proliferations in immunosuppressed pt

A

post-transplant DLBCL

85
Q

CD30 mutation (like Hodgkin’s), YA female; mass, thrombosis, SVC syndrome

A

Type 3 aka Primary Mediastinal BCL

86
Q

Elderly, aggressive CNS disease, treat with intrathecal chemo

A

Double Hit Lymphoma (MYC +/- BCL2 or 6 mutations)

87
Q

EBV infection (especially African)

A

Burkitt’s Lymphoma: Epi/Risk Factors

88
Q

Starry-sky appearance (normal macrophages eat nuclear remnants)

A

Burkitt’s Lymphoma: Histo

89
Q

IgM+, germinal center markers (CD19, 20, 10, Bc16); never express Bcl12

A

Burkitt’s Lymphoma: IHC

90
Q

aggressive chemo, CODOX-M-IVAC (McGrath protocol); very curable

A

Burkitt’s Lymphoma: treatment

91
Q

c-myc translocation from t(8;14), t(8;22), or t(2;8), EBV

A

Burkitt’s Lymphoma: Pathophysiology

92
Q

3 types: HIV-associated, African endemic (mass in mandible), sporadic

A

Burkitt’s Lymphoma: Notes

93
Q

Painless nodes, nodular pattern with small cells

A

Follicular BCL: Signs/Symptoms/Findings

94
Q

CD10(+), t(14;18) common (Bcl2)

A

Follicular BCL: Pathophysiology/Diagnosis

95
Q

Follicular BCL: Prognosis

A

7-9 yrs (BCL subtype)

96
Q

Incurable but can treat with Rituximab, XRT for stage I

A

Follicular: Treatment/Notes

97
Q

Nodular to diffuse, small lymphocytes

A

Mantle Zone: Signs/Symptoms/Findings

98
Q

older males, CD5(+), Cyclin D1(+)

A

Mantle Zone BCL epi

99
Q

translocation of cyclin D1 (11) and heavy-chain Ig(14)

A

Mantle Zone: Pathophysiology/Diagnosis

100
Q

Based on Ki67 levels; high to low: blastic, aggressive, indolent, leukemic)

A

Mantle Zone: Prognosis

101
Q

Bortezomib, aggressive chemo and auto-SC transplant v. watch & wait (depending on variant)

A

Mantle Zone: Treatment/Notes

102
Q

Causes: Sjogren’s, Hashimoto’s (thyroiditis), H. pylori (gastritis), HCV (splenomegaly), c. psittaci (ocular adnexa), borrelia, c. jejuni

A

Extra-Nodal Marginal Zone (MALT): Epi/Risk Factors AND Signs/Symptoms/Findings AND Picture

103
Q

CD20, 19 but no germinal center trademark CD10

A

Extra-Nodal Marginal Zone (MALT): Pathophysiology/Diagnosis

104
Q

Treat antigenic stimulation to cure

A

Extra-Nodal Marginal Zone (MALT): Treatment/Notes

105
Q

Polymorphous small lymphocytes

A

Marginal Zone: Signs/Symptoms/Findings AND Picture

106
Q

increased NFkB via translocations

A

Marginal Zone: Pathophysiology/Diagnosis

107
Q

Look like hybrid of plasma cells and lymphocytes

A

Lymphoplasmacytic Lymphoma: Signs/Symptoms/Findings

108
Q

Igm(+), leads to increased viscosity, neuro/visual problems

A

Lymphoplasmacytic Lymphoma: Pathophysiology/Diagnosis

109
Q

IgM causes Waldenstrom’s macroglobulinemia

A

Lymphoplasmacytic Lymphoma: Treatment/Notes

110
Q

Rare, 5-10% of NHL in US, more in Asia (secondary to Ebv)

A

Peripheral T-Cell Lymphomas (PTCL): Epi/Risk Factors

111
Q

General features: infiltration of plasma cells, B-cells, usually have T-cell markers, TCR rearrangements common

A

Peripheral T-Cell Lymphomas (PTCL): Signs/Symptoms/Findings AND Picture

112
Q

Types: angioimmunoblastic, extranodal NK/T-cell (nasal type), hepatosplenic, subQ, enteropathy-associated

A

Peripheral T-Cell Lymphomas (PTCL): Pathophysiology/Diagnosis

113
Q

Peripheral T-Cell Lymphomas (PTCL): Prognosis

A

Worse than B-cell; median survival is 1-3y, except ALK+ ALCL (5y surivial is 65-90%)

114
Q

Horseshoe-shaped nuclei, CD30+, ugly anaplastic-cells

A

Anaplastic Large Cell: Signs/Symptoms/Findings

115
Q

Brentuximab (anti CD30)

A

Anaplastic Large Cell: Treatment/Notes

116
Q

younger, better prognosis, t(2;5) mutation

A

Anaplastic Large Cell T-Cell lymphoma, ALK+

117
Q

Rash, poor prognosis, no standard Tx

A

Peripheral TCL NOS: Signs/Symptoms/Findings

118
Q

AI syndromes, hemolytic anemia, TCP, rash

A

Angioblastic T-cell lymphoma (AILT) presentation

119
Q

arborized vessels, polymorphous infiltrate, Bc16, CD10; lacking normal CD2, 3, 5, 7

A

Angioblastic T-cell lymphoma (AILT), smear and IHC

120
Q

lymphoma treated with gemcitabine

A

Angioblastic T-cell lymphoma (AILT) treatment

121
Q

Always EBV+, often Asian; large blue granules, CD56+ NK cells, (-) TCR rearrangment

A

Extranodal NK/T-cell lymphoma (nasal type): epi, findings and IHC

122
Q

high dose radiation and chemo; dismal prognosis

A

Extranodal NK/T-cell lymphoma (nasal type): tx and prognosis

123
Q

heptosplenomegaly, coombs (-) hemolytic anemia, purpura/rash, RBCs engulfed by phagocytes, smear is small to medium cells with (=) TCR rearrangment (usually gamma/delta)

A

hepatosplenic t-cell lymphoma

124
Q

progressing skin lesions, history of eczema, plaque leads to tumor leads to LN involvement

A

Mycosis Fungoides: Signs/Symptoms/Findings

125
Q

steroids, topical radiation, phototherapy, topical chemo (early), chemo and transplant (late)

A

Mycosis Fungoides: tx

126
Q

subcutaneous infiltrate, hemaphagocytic syndrome

A

subcutaneous panniculitis-like lymphoma

127
Q

(+) TCR rearrangment (alpha/beta), CD3&8+, no NK cells (CD56-)

A

subcutaneous panniculitis-like lymphoma

128
Q

carribean

A

Adult T-Cell Leukemia/Lymphoma: Epi/Risk Factors

129
Q

long latency (10-30y), rash, hypercalcemia, CNS sx (confusion)

A

Adult T-Cell Leukemia/Lymphoma: Signs/Symptoms/Findings

130
Q

Flower cells

A

Adult T-Cell Leukemia/Lymphoma: Signs/Symptoms/Findings

131
Q

Driven by HTLV-1 via breast milk, blood, sex; TAX(+), CD4(+), CD25(+)

A

Adult T-Cell Leukemia/Lymphoma: Pathophysiology/Diagnosis

132
Q

Adult T-Cell Leukemia/Lymphoma: Prognosis

A

19 weeks!

:(

133
Q

EPOCH or novel therapies

A

Adult T-Cell Leukemia/Lymphoma: Treatment/Notes

134
Q

Young adults w/Slarge mediastinal mass, B-symptoms (pruritus, Pel Ebstein (periodic) fevers, painful nodes upon boozing)

A

Hodgkin’s Lymphoma: Epi/Risk Factors

135
Q

Histo: Reed-Sternberg, owl’s eye nuclei, eosinophils and macs, fibrotic bands

A

Hodgkin’s Lymphoma: Histo

136
Q

10k/year, bimodal (15-35, >50)

A

Hodgkin’s Lymphoma: Epi

137
Q

B-cell origin, but no B- or T-cell markers; CD30(+), CD15(+), PAX(+)

A

Hodgkin’s Lymphoma: Pathophysiology/Diagnosis

138
Q

Based on IPS score, generally good (1% fatal)

A

Hodgkin’s Lymphoma: Prognosis

139
Q

90% cured with ABVD combo chemotherapy (pulmonary toxicity possible)

A

Hodgkin’s Lymphoma: Treatment/Notes

140
Q

Salvage with xplant or Brentuximab

A

Hodgkin’s Lymphoma: Treatment/Notes

141
Q

Rare, 5% of HL, young males, Nodular infiltrates, small lymphocytes, no Reed-Sternberg cells

A

Lymphocyte-Predominant Hodgkin’s Lymphoma: Epi/Risk Factors

142
Q

CD20(+), CD30(=); cervical LAD

A

Lymphocyte-Predominant Hodgkin’s Lymphoma: Pathophysiology/Diagnosis

143
Q

Tx: ABVD (A/Doxorubicin, Bleomycin, Vincristine, Dacarbazine); salvage after PET dx relapse

A

Lymphocyte-Predominant Hodgkin’s Lymphoma: Treatment/Notes

144
Q

most common HL, thick fibrous bands on smear

A

nodular sclerosis HL

145
Q

HIV associated HL

A

mixed cellularity HL

146
Q

mass > 1/3 thoracic cavity, B symptoms or high ESR (inflammation), older (>40-50y)

A

poor prognosis for early HL

147
Q

older than 45, male, albumin under 40, hgb under 105, stage IV, leukocytosis>15k/mm3, lymphs ,600 or <8% WBC count

A

poor prognosis in advanced HL (IPS score)

148
Q

2nd most common heme malignancy; black>W>asian M>F (1.4:1)

A

Multiple Myeloma: Epi/Risk Factors

149
Q

Sx: Calcium is high, renal insufficiency (Cr>2), Anemia (Hgb<10), Bone pain;XR: lucencies = lytic lesions

A

Multiple Myeloma: Signs/Symptoms/Findings

150
Q

Histo: Mott cells, Dutcher bodies, CD38+ (kappa or gamma restricted)

A

Multiple Myeloma: Signs/Symptoms/Findings

151
Q

Dx: monoclonal protein spike in SPEP or UPEP, >10% monoclonal plasma in BM, >1 CRAB

A

Multiple Myeloma: Pathophysiology/Diagnosis

152
Q

MM prognosis

A

38.2% 5yr OS if treated, 6mo if not; Chromosome abnormality in 90% of pts

153
Q

t(4;14)(p16;q32), t(14;16)(q32;q23) and -17p13 (aka p53)

A

bad prognosis in MM

154
Q

deletion of 13q14

A

intermediate prognosis in MM

155
Q

no cytogenic abnormalities in MM

A

good prognosis

156
Q

chemo and biphosphonates

A

tx for MM bone disease complications

157
Q

lenalidomide, bortezomib

A

Multiple Myeloma: Treatment/Notes

158
Q

before day 100

A

acute GVHD timing

159
Q

inflammatory attack by donor T-cells on host organs (gut, liver, skin)

A

acute GVHD pathogenesis

160
Q

erythematous maculopaular rash, increased bilirubin, diarrhea

A

acute GVHD presentation

161
Q

prevent with cyclosporine +/- MTX, treat with prednisone

A

acute GVHD tx

162
Q

after day 100

A

chronic GVHD timing

163
Q

defect in immune reconstitution leads to dysregulation, impaired organ function, decreased survival

A

chronic GVHD pathogenesis

164
Q

AI symptoms in skin, eyes, gut, mouth, liver, MSK, lungs, GU; scleroderma, skin and deep sclerosis

A

chronic GVHD presentation

165
Q

risk of rejection is proportional to

A

MHC/HLA mismatch

Oncology (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions